FDA Expands Vertex’s Casgevy Gene Therapy to Young Children

On July 1, 2026 the U.S. Food and Drug Administration issued an expanded approval for Vertex Pharmaceuticals’ gene‑editing treatment Casgevy, allowing its use in children as young as two years old who have sickle cell disease or transfusion‑dependent beta thalassemia. This marks the first time a CRISPR‑based therapy has been authorized for such an early age group in the United States.

Casgevy, originally cleared in 2023 for patients twelve years and older, works by extracting a patient’s own hematopoietic stem cells, editing the DNA with the CRISPR/Cas9 system, and then returning the modified cells to the bone marrow. The edit increases production of fetal hemoglobin, which improves oxygen delivery and reduces the painful vaso‑occlusive crises of sickle cell disease as well as the transfusion burden of beta thalassemia.

Clinical data supporting the label expansion are compelling. In a Phase III trial for sickle cell disease involving eleven children aged five to under twelve, eight evaluable participants remained free of vaso‑occlusive crises for at least one year after treatment. A separate Phase III study of fifteen patients with beta thalassemia aged five to twelve showed that eight of nine evaluable participants achieved transfusion independence for twelve consecutive months.

Vertex’s CEO Reshma Kewalramani highlighted the consistency of results across age groups, calling the outcomes “remarkable” and emphasizing the therapy’s potential to provide durable, life‑changing benefits for patients who previously had limited options. The FDA’s decision also reflects its broader commitment to accelerating advanced therapies for rare diseases, including a new fast‑track pathway announced in late 2025.

Access considerations are already taking shape. In the United Kingdom the therapy’s list price is about £1.65 million per patient, yet the National Health Service has secured a reimbursement agreement that makes the treatment available at no cost to eligible patients. In the United States, approximately 90 % of patients with insurance have secured reimbursement for Casgevy, according to Vertex’s reports.

Beyond the immediate clinical impact, the approval signals a turning point for gene‑editing technology in mainstream medicine. It demonstrates that precise, one‑time genomic interventions can move from experimental trials to real‑world use, offering hope to millions affected by inherited blood disorders worldwide.

As the medical community integrates this new therapeutic option, caregivers and clinicians will need to navigate eligibility criteria, long‑term monitoring, and the ethical responsibilities that accompany genome‑editing. Nonetheless, the expanded availability of Casgevy represents a significant stride toward curative care for the youngest patients with sickle cell disease and beta thalassemia.